Suppliers / EUROAPI Hungary

EUROAPI Hungary

Hungary Updated 9 July 2026

EUROAPI Hungary is an API manufacturer based in Hungary. It holds 13 active US drug master files and 7 valid CEPs across a filed portfolio of 15 molecules. Its most recent recorded inspection, by US FDA, closed on 21 June 2019 as NAI.

13
active US DMFs
7
valid CEPs
2
registered plants 1 with an FDA FEI number
6
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 21 June 2019 NAI US FDA
  • 20 April 2018 VAI US FDA
  • 30 May 2014 NAI US FDA
  • 4 February 2010 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Budapest, Hungary Not on file
Hungary, Hungary 3002806675

What they file, and where

Molecule Regulators Docs
Alprostadil EDQM, SFDA (Saudi Arabia), US FDA 4
Bimatoprost SFDA (Saudi Arabia), US FDA 2
Irbesartan EDQM, US FDA 2
Latanoprost EDQM, US FDA 2
Selegiline EDQM, US FDA 2
Carboprost US FDA 1
Dinoprost EDQM 1
Dinoprostone US FDA 1
Hydroxychloroquine US FDA 1
Iloprost US FDA 1
Show all 15 molecules on file
Olmesartan US FDA 1
Olmesartan Medoxomil EDQM 1
Pentamidine Diisetionate EDQM 1
Travoprost US FDA 1
Treprostinil US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 6 None

Comparing suppliers?

Choose your molecules and target markets. EUROAPI Hungary comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 21 June 2019.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability